血清钙卫蛋白与ANCA相关性血管炎肾功能下降:MAINRITSAN试验的事后分析
该事后分析纳入76例诱导缓解后接受利妥昔单抗或硫唑嘌呤维持治疗的ANCA相关性血管炎患者,评估血清钙卫蛋白水平能否预测肾功能下降。结果显示,第6个月钙卫蛋白较基线升高与随后12个月肾功能下降风险升高相关(校正后OR 6.50,95%CI 1.7至24.9,P=0.006);蛋白酶3-ANCA患者中钙卫蛋白升高与复发风险升高相关(OR 5.6,95%CI 1.0至31.2,P=0.03)。
要点
- 第6个月血清钙卫蛋白较基线升高与随后12个月肾功能下降风险升高相关(校正后OR 6.50,95%CI 1.7至24.9,P=0.006)。
- 蛋白酶3-ANCA患者中血清钙卫蛋白升高与复发风险升高相关(OR 5.6,95%CI 1.0至31.2,P=0.03)。
- 肾功能下降患者第6个月钙卫蛋白较基线升高7940(-226.0,28691)ng/ml,无下降患者为-4800(-18777,3708)ng/ml,组间P<0.001。
核心结论
- 在ANCA相关性血管炎缓解维持治疗期间,第6个月血清钙卫蛋白较入组时升高与随后12个月肾功能下降风险升高相关。
研究设计与样本
- MAINRITSAN试验的事后分析,纳入76例诱导治疗后达完全缓解、随机分配接受利妥昔单抗或硫唑嘌呤维持治疗的ANCA相关性血管炎患者。
- 在入组时和第6个月检测血清钙卫蛋白水平。
- 肾功能下降定义为估算肾小球滤过率(eGFR)下降25%且eGFR类别改变,或eGFR下降15 mL/min/1.73 m2。
- 复发定义为归因于活动性血管炎的伯明翰血管炎活动度评分>0。
主要发现
- 肾功能下降患者血清钙卫蛋白从基线至第6个月升高7940(-226.0,28691)ng/ml,无肾功能下降患者为-4800(-18777,3708)ng/ml,P<0.001。
- 钙卫蛋白水平升高与随后肾功能下降风险升高相关,校正后OR 6.50(95%CI 1.7至24.9),P=0.006。
- 蛋白酶3-ANCA患者中血清钙卫蛋白水平升高与复发风险升高相关,OR 5.6(95%CI 1.0至31.2),P=0.03。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Serum calprotectin appears to be an interesting biomarker associated with renal vascular disease activity in antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). The aim of this study was to assess whether serum calprotectin levels can predict decline in renal function in AAV patients receiving maintenance therapy. METHODS: Serum calprotectin levels were assessed at inclusion and month 6 in AAV patients, in complete remission after induction therapy, randomly assigned to rituximab or azathioprine. Renal function decline was defined as a 25% decrease in estimated glomerular filtration rate (eGFR) and a change in the eGFR category, or a decrease of 15 mL/min/1.73 m2. Relapse was defined as a Birmingham Vasculitis Activity Score >0 attributable to active vasculitis. RESULTS: Seventy-six AAV were included. Serum calprotectin increased from baseline to month 6 in patients with renal function decline (7940 (-226.0, 28 691) ng/ml vs -4800 (-18 777, 3708) ng/ml; p<0.001). An increase of calprotectin level was associated with a higher risk of subsequent renal function decline even after adjustment (OR 6.50 (95% CI 1.7 to 24.9) p=0.006). A significantly higher risk of relapse was observed in proteinase 3- AAV patients with an increase of serum calprotectin levels (OR 5.6 (95% CI 1.0 to 31.2), p=0.03). CONCLUSION: An increase in serum calprotectin by month 6 compared with inclusion during remission-maintenance therapy in AAV was associated with a higher risk of renal function decline in the following 12 months. TRIAL REGISTRATION NUMBER: NCT00748644.
引用
- Romand X, Paclet MH, Chuong MV, et al. Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial. RMD Open. 2023. PMID: 37903568. doi:10.1136/rmdopen-2023-003477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。